Content
All Posts > Content under Healthcare
Aetna Inc - Chart Of The Day
Article By:
Jim Van Meerten
Read
Thursday, May 11, 2017 8:12 PM EDT
Since the Trend Spotter signaled a buy on 4/24 the stock gained 9.95%.
In this article: AET
Cannabis Now A Global Investment Opportunity
Article By:
Alan Brochstein
Read
Thursday, May 11, 2017 6:39 PM EDT
The Canadian market continues to evolve as a leader in the global cannabis industry, with legalization efforts likely to result in legal sales commencing in about a year.
Puma (PBYI) Q1 Loss Narrows, Focus Remains On Neratinib
Article By:
Zacks Investment Research
Read
Thursday, May 11, 2017 10:10 AM EDT
Puma Biotechnology, Inc. reported a first-quarter 2017 loss of $1.97 per share narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.
Teva Pharmaceutical Industries Ltd. (ADR) Backs Forecast Amid Mixed Q1
Article By:
Lorimer Wilson
Read
Thursday, May 11, 2017 10:00 AM EDT
The Israeli generic pharmaceutical giant, Teva Pharmaceutical Industries Ltd (ADR) posted mixed first quarter earnings but backed its full-year outlook, as a recent acquisition began to hugely bolster its top line.
In this article: TEVA
Consuming Oxygen
Article By:
Marvin R Clark
Read
Thursday, May 11, 2017 12:27 AM EDT
As US equity markets continue to price to perfection a grab bag of promised corporate giveaways, a group of researchers at the International Monetary Fund (IMF) had the temerity to ask last month – what could possibly go wrong.
Hologic Beats Q1 Sales And EPS
Article By:
Rod Raynovich
Read
Wednesday, May 10, 2017 10:28 PM EDT
Hologic's revenues Increased 3.2% and GAAP diluted Earnings Increased 666.7% Compared to Prior Year Period. The stock closed down 2% AH to $45.
4 Top-Ranked Liquid Stocks For A Winning Portfolio
Article By:
Zacks Investment Research
Read
Wednesday, May 10, 2017 3:04 PM EDT
Liquidity of a stock is an important yardstick that many investors tend to ignore. It primarily indicates a company’s capability to meet debt obligations by converting assets into liquid cash and equivalents.
How BioSig's PURE EP Beats The Competition
Article By:
Jason Napodano
Read
Wednesday, May 10, 2017 10:24 AM EDT
The market is asleep on BioSig right now. Perhaps they see an upstart player not capable of competing with behemoths like GE and J&J.
In this article: BSGM
5-Star Insiders Are Snapping Up These Hot Stocks
Mylan Vs. Teva: Which Is The Better Generics Stock Ahead Of Earnings?
Article By:
Swarup Gupta
Read
Wednesday, May 10, 2017 4:10 AM EDT
Coming to the two generics producers, both Mylan and Teva are undervalued relative to their broader industry. However, Teva holds the edge here with a lower EV/EBITDA value of 7.58, compared to Mylan’s value of 8.12.
Endo Q1 Earnings Beat Estimates, Revenues In Line
Article By:
Zacks Investment Research
Read
Tuesday, May 9, 2017 10:21 AM EDT
Endo surpassed first-quarter 2017 earnings. The company reported EPS of $1.23 while our consensus called for EPS of $1.12.
In this article: ENDP
Why Radicava Approval Is Good News For BrainStorm Cell Therapeutics
Article By:
Jason Napodano
Read
Tuesday, May 9, 2017 10:13 AM EDT
BrainStorm is expanding its management team and focusing on securing non-dilutive capital. The company has the cash to begin the study and an excellent track record of bringing in non-dilutive grants to keep shareholder dilution to a minimum.
In this article: BCLI
Allergan Lifts Guidance As Q1 Earnings Beat The Street
Article By:
Lorimer Wilson
Read
Tuesday, May 9, 2017 8:53 AM EDT
The Dublin, Ireland-based pharmaceuticals giant, Allergan plc. posted better than expected first quarter earnings results and lifted its full-year outlook, amid strong demand for its facial aesthetics products.
In this article: AGN